- Home
- RBLX vs BIIB Comparison
RBLX vs BIIB Comparison
Compare RBLX & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBLX
- BIIB
- Stock Information
- Founded
- RBLX 2006
- BIIB 1978
- Country
- RBLX United States
- BIIB United States
- Employees
- RBLX N/A
- BIIB N/A
- Industry
- RBLX EDP Services
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- RBLX Technology
- BIIB Health Care
- Exchange
- RBLX Nasdaq
- BIIB Nasdaq
- Market Cap
- RBLX 55.5B
- BIIB 18.8B
- IPO Year
- RBLX 2021
- BIIB 1991
- Fundamental
- Price
- RBLX $124.43
- BIIB $124.99
- Analyst Decision
- RBLX Strong Buy
- BIIB Buy
- Analyst Count
- RBLX 22
- BIIB 27
- Target Price
- RBLX $88.43
- BIIB $188.17
- AVG Volume (30 Days)
- RBLX 7.8M
- BIIB 1.2M
- Earning Date
- RBLX 07-31-2025
- BIIB 07-31-2025
- Dividend Yield
- RBLX N/A
- BIIB N/A
- EPS Growth
- RBLX N/A
- BIIB 26.39
- EPS
- RBLX N/A
- BIIB 10.12
- Revenue
- RBLX $3,835,886,000.00
- BIIB $9,816,400,000.00
- Revenue This Year
- RBLX $51.83
- BIIB N/A
- Revenue Next Year
- RBLX $21.39
- BIIB N/A
- P/E Ratio
- RBLX N/A
- BIIB $12.35
- Revenue Growth
- RBLX 30.24
- BIIB 1.59
- 52 Week Low
- RBLX $35.30
- BIIB $110.04
- 52 Week High
- RBLX $124.60
- BIIB $236.48
- Technical
- Relative Strength Index (RSI)
- RBLX 81.26
- BIIB 41.14
- Support Level
- RBLX $102.73
- BIIB $132.37
- Resistance Level
- RBLX $108.00
- BIIB $137.84
- Average True Range (ATR)
- RBLX 4.19
- BIIB 4.16
- MACD
- RBLX 1.23
- BIIB -0.68
- Stochastic Oscillator
- RBLX 99.31
- BIIB 7.82
About RBLX Roblox Corporation
Roblox operates a free-to-play online video game platform with about 85 million daily active users. This platform has spawned a virtual universe and a Roblox economy based on the Robux currency. The platform houses millions of games from a wide range of creators spanning from young gamers themselves to professional development studios. Roblox offers creators the tools, publishing abilities, and platform for their games, enabling anyone to create a game. Creators earn money when gamers make optional in-game purchases within their games and by offering space for real-world advertising, and Roblox earns revenue primarily by taking a cut of these earnings.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.